• H Hauner.
• Institut für Ernährungsmedizin, Klinikum rechts der Isar, München, Deutschland. hans.hauner@tum.de.
• Internist (Berl). 2021 Dec 1; 62 (12): 1354-1359.

AbstractObesity and its comorbidities represent a worldwide growing health challenge. In Germany, at least 15 million people are suffering from this disease. To date, lifestyle modification is the most frequently used treatment modality, but offers only limited success concerning both the extent and the sustainability of weight loss, while surgical interventions are restricted to people with severe obesity (body mass index ≥40 kg/m2). For this reason, there are huge efforts to develop pharmacological options for better and clinically meaningful weight management. At present, only a few compounds (orlistat, liraglutide, amfepramon) are available for adjunct drug treatment of obesity in Germany. However, new principles and compounds that could revolutionize obesity management in the years to come are on the horizon. For alternative "slimming drugs", mainly dietary supplements, scientific evidence is lacking on efficacy or clinically meaningful weight loss.© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

14 keywords...

hide…